1. Piketty ML, Polak M, Flechtner I, Gonzales-Briceño L, Souberbielle JC. False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences. Clin Chem Lab Med. 2017; 55:780–788. PMID:
27732554.
2. Livaniou E, Evangelatos GP, Ithakissios DS, Yatzidis H, Koutsicos DC. Serum biotin levels in patients undergoing chronic hemodialysis. Nephron. 1987; 46:331–332. PMID:
3627330.
3. Grimsey P, Frey N, Bendig G, Zitzler J, Lorenz O, Kasapic D, et al. Population pharmacokinetics of exogenous biotin and the relationship between biotin serum levels and in vitro immunoassay interference. Int J Pharmacokinet. 2017; 2:247–256.
4. Peyro Saint Paul L, Debruyne D, Bernard D, Mock DM, Defer GL. Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis. Expert Opin Drug Metab Toxicol. 2016; 12:327–344. PMID:
26699811.
5. Lipner SR. Rethinking biotin therapy for hair, nail, and skin disorders. J Am Acad Dermatol. 2018; 78:1236–1238. PMID:
29438761.
6. Katzman BM, Lueke AJ, Donato LJ, Jaffe AS, Baumann NA. Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department. Clin Biochem. 2018; 60:11–16. PMID:
30036510.
7. Gifford JL, Sadrzadeh SMH, Naugler C. Biotin interference: underrecognized patient safety risk in laboratory testing. Can Fam Physician. 2018; 64:370. PMID:
29760259.
8. Trambas C, Lu Z, Yen T, Sikaris K. Depletion of biotin using streptavidin-coated microparticles: a validated solution to the problem of biotin interference in streptavidin–biotin immunoassays. Ann Clin Biochem. 2018; 55:216–226. PMID:
28406314.